Advancing the minimal residual disease concept in acute myeloid leukemia

Seminars in Hematology

Volumn 52, Issue 3, 2015, Pages 184-192

  Hokland, Peter ^a   Ommen, Hans B ^a   Mulé, Matthew P ^b   Hourigan, Christopher S ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; CANCER PROGNOSIS; CLINICAL ASSESSMENT; FLOW CYTOMETRY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEALTH CARE COST; HEALTH CARE PRACTICE; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; NEXT GENERATION SEQUENCING; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SOMATIC MUTATION; ECONOMICS; LEUKEMIA, MYELOID, ACUTE; RECURRENT DISEASE;

FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; RECURRENCE;

EID: 84937391836     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.04.001     Document Type: Review

References (100)

1. Hokland P., Cotter F. Readying the minimal residual disease concept in acute myeloid leukaemia for prime time-the American way. Br J Haematol. 2013, 162(4):429-430.
2. Grimwade D., Freeman S.D. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?. Blood 2014, 124(23):3345-3355.
3. Hokland P., Ommen H.B., Nyvold C.G., Roug A.S. Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission-methodologies in relation to their clinical situation. Br J Haematol. 2012, 158(5):569-580.
4. Hokland P., Ommen H.B. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood 2011, 117(9):2577-2584.
5. Roug A.S., Hansen M.C., Nederby L., Hokland P. Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age. Br J Haematol 2014, 167(2):162-176.
6. Hourigan C.S., Karp J.E. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 2013, 10(8):460-471.
7. Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematology Am Soc Hematol Educ Program 2012, 2012:35-42.
8. Coustan-Smith E., Campana D. Should evaluation for minimal residual disease be routine in acute myeloid leukemia?. Curr Opin Hematol 2013, 20(2):86-92.
9. Kayser S., Schlenk R.F., Grimwade D., Yosuico V.E., Walter R.B. Minimal residual disease-directed therapy in acute myeloid leukemia. Blood 2015, 125(15):2331-2335.
10. Appelbaum F.R. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Best Pract Res Clin Haematol 2013, 26(3):279-284.
11. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368(22):2059-2074.
12. Hughes A.E., Magrini V., Demeter R., et al. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet 2014, 10(7):e1004462.
13. Klco J.M., Spencer D.H., Miller C.A., et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014, 25(3):379-392.
14. Goswami M., Hensel N., Smith B.D., et al. Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia 2014, 28(5):1167-1170.
15. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481(7382):506-510.
16. Welch J.S., Ley T.J., Link D.C., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150(2):264-278.
17. Gabert J., Beillard E., van der Velden V.H., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003, 17(12):2318-2357.
18. Tobal K., Frost L., Liu Yin J.A. Quantification of DEK-CAN fusion transcript by real-time reverse transcription polymerase reaction in patients with t(6;9) acute myeloid leukemia. Haematologica 2004, 89(10):1267-1269.
19. Gorello P., Cazzaniga G., Alberti F., et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006, 20(6):1103-1108.
20. Cilloni D., Gottardi E., De Micheli D., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002, 16(10):2115-2121.
21. Inoue K., Sugiyama H., Ogawa H., et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994, 84(9):3071-3079.
22. Steinbach D., Bader P., Willasch A., et al. Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia. Clin Cancer Res 2015, 21(6):1353-1359.
23. Goswami M., McGowan K.S., Lu K., et al. A multigene array for measurable residual disease detection in AML patients undergoing SCT. Bone Marrow Transplant 2015 Feb 9, [Epub ahead of print]. 10.1038/bmt.2014.326.
24. Hourigan C.S. Next Generation MRD. Biol Blood Marrow Transplant 2014, 20(9):1259-1260.
25. Logan A.C., Vashi N., Faham M., et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant 2014, 20(9):1307-1313.
26. Logan A.C., Zhang B., Narasimhan B., et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia 2013, 27(8):1659-1665.
27. Thol F., Kolking B., Damm F., et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer 2012, 51(7):689-695.
28. Ladetto M., Bruggemann M., Monitillo L., et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2014, 28(6):1299-1307.
29. Duployez N., Nibourel O., Marceau-Renaut A., et al. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. Am J Hematol 2014, 89(6):610-615.
30. Faham M., Zheng J., Moorhead M., et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012, 120(26):5173-5180.
31. Mailankody S., Korde N., Lesokhin A.M., et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 2015 Jan 27, [Epub ahead of print]. 10.1038/nrclinonc.2014.239.
32. Martinez-Lopez J., Lahuerta J.J., Pepin F., et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014, 123(20):3073-3079.
33. Schrappe M. Detection and management of minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2014, 2014(1):244-249.
34. Weng W.K., Armstrong R., Arai S., Desmarais C., Hoppe R., Kim Y.H. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Sci Transl Med 2013, 5(214):214ra171.
35. Wu D., Emerson R.O., Sherwood A., et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res 2014, 20(17):4540-4548.
36. Wu D., Sherwood A., Fromm J.R., et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012, 4(134):134ra163.
37. Young A.L., Wong T.N., Hughes A.E., et al. Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing. Leukemia 2015 Feb 3, [Epub ahead of print]. 10.1038/leu.2015.17.
38. Robasky K., Lewis N.E., Church G.M. The role of replicates for error mitigation in next-generation sequencing. Nat Rev Genet 2014, 15(1):56-62.
39. Lou D.I., Hussmann J.A., McBee R.M., et al. High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. Proc Natl Acad Sci U S A 2013, 110(49):19872-19877.
40. Ploen G.G., Nederby L., Guldberg P., et al. Persistence of DNMT3A mutations at long-term remission in adult patients with AML. Br J Haematol 2014, 167(4):478-486.
41. Jaiswal S., Fontanillas P., Flannick J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014, 371(26):2488-2498.
42. Genovese G., Kahler A.K., Handsaker R.E., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014, 371(26):2477-2487.
43. Xie M., Lu C., Wang J., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014, 20(12):1472-1478.
44. Busque L., Patel J.P., Figueroa M.E., et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012, 44(11):1179-1181.
45. Corces-Zimmerman M.R., Hong W.J., Weissman I.L., Medeiros B.C., Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014, 111(7):2548-2553.
46. Jan M., Snyder T.M., Corces-Zimmerman M.R., et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012, 4(149):149ra118.
47. Pant S., Weiner R., Marton M.J. Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol 2014, 4:78.
48. Chin E.L., da Silva C., Hegde M. Assessment of clinical analytical sensitivity and specificity of next-generation sequencing for detection of simple and complex mutations. BMC Genet 2013, 14:6.
49. Wilson C.A., Simonyan V. FDA's Activities Supporting Regulatory Application of "Next Gen" Sequencing Technologies. PDA J Pharm Sci Technol 2014, 68(6):626-630.
50. Jourdan E., Boissel N., Chevret S., et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013, 121(12):2213-2223.
51. Stentoft J., Hokland P., Ostergaard M., Hasle H., Nyvold C.G. Minimal residual core binding factor AMLs by real time quantitative PCR-initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res 2006, 30(4):389-395.
52. Ommen H.B., Nyvold C.G., Braendstrup K., et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008, 141(6):782-791.
53. Bornhauser M., Oelschlaegel U., Platzbecker U., et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica 2009, 94(11):1613-1617.
54. Ommen H.B., Schnittger S., Jovanovic J.V., et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010, 115(2):198-205.
55. Sockel K., Wermke M., Radke J., et al. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica 2011, 96(10):1568-1570.
56. Ommen H.B., Hokland P., Haferlach T., et al. Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene. Br J Haematol 2014, 165(5):618-628.
57. Platzbecker U., Wermke M., Radke J., et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012, 26(3):381-389.
58. Ommen H.B., Touzart A., MacIntyre E., et al. The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients. Eur J Haematol 2015 Jan 21, [Epub ahead of print]. 10.1111/ejh.12511.
59. Schnittger S., Kern W., Tschulik C., et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009, 114(11):2220-2231.
60. Venditti A., Buccisano F., Maurillo L., et al. Risk-adapted, MRD-refined therapeutic approach for the treatment of acute myeloid leukemia: from a single center experience to the Cooperative Gimema Protocol AML1310. ASH Annual Meeting Abstracts 2012, 120(21):1422.
61. Ostergaard M., Nyvold C.G., Jovanovic J.V., et al. Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. Leukemia 2011, 25(7):1168-1173.
62. Nerich V., Lioure B., Rave M., et al. Induction-related cost of patients with acute myeloid leukaemia in France. Int J Clin Pharm 2011, 33(2). 191-19.
63. Leunis A., Blommestein H.M., Huijgens P.C., Blijlevens N.M., Jongen-Lavrencic M., Uyl-de Groot C.A. The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leuk Res 2013, 37(3):245-250.
64. Bradley C.J., Dahman B., Jin Y., Shickle L.M., Ginder G.D. Acute myeloid leukemia. Cancer 2011, 117(20):4772-4778.
65. Thao V., Kozhimannil K.B., Thomas W., Golberstein E. Variation in inpatient costs of hematopoietic cell transplantation among transplant centers in the United States. JAMA Intern Med 2014, 174(8):1409-1412.
66. Khera N., Zeliadt S.B., Lee S.J. Economics of hematopoietic cell transplantation. Blood 2012, 120(8):1545-1551.
67. Sanchez-Ortega I., Patino B., Munoz C., et al. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation. J Med Econ 2013, 16(6):736-743.
68. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2):122-133.
69. Masmas T.N., Madsen H.O., Petersen S.L., et al. Evaluation and automation of hematopoietic chimerism analysis based on real-time quantitative polymerase chain reaction. Biol Blood Marrow Transplant 2005, 11(7):558-566.
70. Sheridan C. Illumina claims $1,000 genome win. Nat Biotechnol 2014, 32(2):115.
71. Walter R.B., Appelbaum F.R., Tallman M.S., Weiss N.S., Larson R.A., Estey E.H. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood 2010, 116(14):2420-2428.
72. Hourigan C.S., McCarthy P., de Lima M. Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014, 20(2):154-163.
73. Butturini A., Klein J., Gale R.P. Modeling minimal residual disease (MRD)-testing. Leuk Res 2003, 27(4):293-300.
74. Bisel H.F. Criteria for the evaluation of response to treatment in acute leukemia. Blood 1956, 11:676-677.
75. Zeleznikova T., Babusikova O. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia. Neoplasma 2006, 53(6):500-506.
76. Cilloni D., Renneville A., Hermitte F., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009, 27(31):5195-5201.
77. Krönke J., Schlenk R.F., Jensen K.O., et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011, 29(19):2709-2716.
78. Shayegi N., Kramer M., Bornhauser M., et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood 2013, 122(1):83-92.
79. Campana D., Leung W. Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol 2013, 162(2):147-161.
80. Al-Mawali A., Gillis D., Hissaria P., Lewis I. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol 2008, 129(6):934-945.
81. Welch J.S. Mutation position within evolutionary subclonal architecture in AML. Semin Hematol 2014, 51(4):273-281.
82. Shih L.Y., Huang C.F., Wu J.H., et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002, 100(7):2387-2392.
83. Kottaridis P.D., Gale R.E., Langabeer S.E., Frew M.E., Bowen D.T., Linch D.C. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002, 100(7):2393-2398.
84. Nazha A., Cortes J., Faderl S., et al. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica 2012, 97(8):1242-1245.
85. Miyamoto T., Weissman I.L., Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A 2000, 97(13):7521-7526.
86. Miyamoto T., Nagafuji K., Akashi K., et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996, 87(11):4789-4796.
87. Tobal K., Liu Yin J.A. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL. Leukemia 1998, 12(9):1349-1354.
88. Tobal K., Saunders M.J., Grey M.R., Yin J.A. Persistence of RAR alpha-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. Br J Haematol 1995, 90(3):615-618.
89. Jain P., Kantarjian H., Patel K., et al. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma 2014, 55(6):1337-1344.
90. Kristensen T., Moller M.B., Friis L., Bergmann O.J., Preiss B. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. Eur J Haematol 2011, 87(5):400-408.
91. Shayegi N., Kramer M., Bornhauser M., et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood 2013, 122(1):83-92.
92. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352(3):254-266.
93. Bene M.C., Kaeda J.S. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. Haematologica 2009, 94(8):1135-1150.
94. Cui W., Zhang D., Cunningham M.T., Tilzer L. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings. Int J Lab Hematol 2014, 36(6):636-649.
95. Langebrake C., Brinkmann I., Teigler-Schlegel A., et al. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry B Clin Cytom 2005, 63(1):1-9.
96. Voskova D., Schoch C., Schnittger S., Hiddemann W., Haferlach T., Kern W. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom 2004, 62(1):25-38.
97. Cheng M.J., Hourigan C.S., Smith T.J. Adult Acute Myeloid Leukemia Long-term Survivors. J Leuk (Los Angel) 2014, 2(2):26855.
98. Ouyang J., Goswami M., Tang G., et al. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. Am J Hematol 2015 Mar 2, [Epub ahead of print]. 10.1002/ajh.23988.
99. Public Workshop on Minimal Residual Disease (MRD) as a Surrogate Endpoint in Acute Myeloid Leukemia (AML).March 4th, 2013. : FDA; 2013. http://www.fda.gov/Drugs/NewsEvents/ucm341421.htm.
100. Goldman J.M., Gale R.P. What does MRD in leukemia really mean?. Leukemia 2014, 28(5):1131.